Human Chorionic Gonadotropin (hCG)

By RRM Academy Reviewed by Dr. Naomi Whittaker, MD, Board-Certified OBGYN, MIGS, NFPMC, FCI Updated May 7, 2026

Human chorionic gonadotropin is produced by the developing trophoblast immediately after implantation. Its rise in early pregnancy is the basis of every pregnancy test. But hCG also has important therapeutic applications in RRM practice that extend well beyond diagnosis.

Structurally, hCG closely resembles LH. It binds the same receptors. This means exogenous hCG can substitute for the mid-cycle LH surge to trigger ovulation, or it can provide ongoing luteal phase support after ovulation when the corpus luteum needs reinforcement. Both uses are part of restorative care.

In recurrent pregnancy loss, low early-pregnancy hCG can reflect inadequate trophoblast support, which is often related to insufficient progesterone or underlying endometrial pathology. Targeted hCG supplementation in early pregnancy has been studied as a support strategy for women with a history of recurring loss. Quenby and Farquharson published a controlled trial examining this approach in 1994.⁶⁰ The rationale is restorative: support the corpus luteum and the developing pregnancy rather than waiting for it to fail.

hCG injections are also used in NaProTechnology protocols to assist with ovulation induction and to support the luteal phase in women with documented deficiency. The timing is cycle-charted, not arbitrary. That precision is what makes the intervention restorative rather than generic hormonal loading.

Serial quantitative hCG levels in early pregnancy are one of the most important early monitoring tools in RRM care. A doubling time that is slower than expected, or a plateau, prompts early investigation and intervention rather than a "wait and see" approach.

This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.